Evoke Pharma, Inc. (EVOK) Forecasted to Earn FY2017 Earnings of ($0.65) Per Share
Evoke Pharma, Inc. (NASDAQ:EVOK) – Research analysts at FBR & Co issued their FY2017 earnings per share (EPS) estimates for Evoke Pharma in a research report issued on Wednesday. FBR & Co analyst D. Buck expects that the specialty pharmaceutical company will post earnings per share of ($0.65) for the year. FBR & Co has a “Buy” rating and a $10.00 price objective on the stock. FBR & Co also issued estimates for Evoke Pharma’s FY2018 earnings at ($0.33) EPS, FY2019 earnings at $0.00 EPS, FY2020 earnings at $0.00 EPS and FY2021 earnings at $1.10 EPS.
EVOK has been the topic of several other research reports. HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Evoke Pharma in a report on Tuesday, August 15th. Zacks Investment Research cut shares of Evoke Pharma from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. ValuEngine upgraded shares of Evoke Pharma from a “strong sell” rating to a “sell” rating in a report on Friday, July 7th. Northland Securities reiterated a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Wednesday, October 18th. Finally, Seaport Global Securities reiterated a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $8.86.
Shares of Evoke Pharma (NASDAQ:EVOK) opened at 3.44 on Monday. Evoke Pharma has a 1-year low of $1.35 and a 1-year high of $4.55. The company’s market capitalization is $52.93 million. The stock has a 50 day moving average of $3.35 and a 200-day moving average of $2.77.
Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.15). During the same quarter in the prior year, the company earned ($0.41) EPS.
An institutional investor recently raised its position in Evoke Pharma stock. State Treasurer State of Michigan boosted its holdings in Evoke Pharma, Inc. (NASDAQ:EVOK) by 37.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 400,000 shares of the specialty pharmaceutical company’s stock after buying an additional 108,034 shares during the quarter. State Treasurer State of Michigan owned 2.60% of Evoke Pharma worth $1,024,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 12.88% of the company’s stock.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.